Impact of a Computerized Antithrombotic Risk Assessment Tool on the Prescription of Thromboprophylaxis in Atrial Fibrillation: Hospital Setting.
The computerized antithrombotic risk assessment tool (CARAT) is an online decision-support algorithm that facilitates a systematic review of a patient's stroke risk, bleeding risk, and pertinent medication safety considerations, to generate an individualized treatment recommendation. The CARAT was prospectively applied across 2 hospitals in the greater Sydney area. Its impact on antithrombotics utilization for thromboprophylaxis in patients with nonvalvular atrial fibrillation was evaluated. Factors influencing prescribers' treatment selection were identified. The CARAT recommended a change in baseline therapy for 51.8% of patients. Among anticoagulant-eligible patients (ie, where the risk of stroke outweighed the risk of bleeding) using "nil therapy" or antiplatelet therapy at baseline, the CARAT recommended an upgrade to warfarin in 60 (30.8%) patients. For those in whom the bleeding risk outweighed the stroke risk, the CARAT recommended a downgrade from warfarin to safer alternatives (eg, aspirin) in 37 (19%) patients. Among the "most eligible" (ie, high stroke risk, low bleeding risk, no contraindications; n = 75), the CARAT recommended warfarin for all cases. Discharge therapy observed a marginal increase in anticoagulation prescription in eligible patients (n = 116; 57.8% vs 64.7%, P = .35) compared to baseline. Predictors of warfarin use (vs antiplatelets) included congestive cardiac failure, diabetes mellitus, and polypharmacy. The CARAT was able to optimize the selection of therapy, increasing anticoagulant use among eligible patients. With the increasing complexity of decision-making, such tools may be useful adjuncts in therapy selection in atrial fibrillation. Future studies should explore the utility of such tools in selecting therapies from within an expanded treatment armamentarium comprising the non-vitamin K antagonist oral anticoagulants.
1 Graduate School of Health, Discipline of Pharmacy, University of Technology Sydney, Ultimo, New South Wales, Australia.
E
E
Pandya
2 Northern Sydney Local Health District, St Leonards, New South Wales, Australia.
N
N
Masood
1 Graduate School of Health, Discipline of Pharmacy, University of Technology Sydney, Ultimo, New South Wales, Australia.
Y
Y
Wang
3 Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia.
I
I
Krass
1 Graduate School of Health, Discipline of Pharmacy, University of Technology Sydney, Ultimo, New South Wales, Australia.|4 Department of Pharmacy, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
B
B
Bajorek
D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy*; D003936:Diagnosis, Computer-Assisted / Q000379:methods*; D011307:Drug Prescriptions; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D018570:Risk Assessment; D013927:Thrombosis / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
D000925:Anticoagulants; D014859:Warfarin
anticoagulants; antithrombotic therapy; atrial fibrillation; stroke; thromboprophylaxis; warfarin
Stroke. 2000 Jun;31(6):1217-22
10835435
JAMA. 2001 Jun 13;285(22):2864-70
11401607
BMC Fam Pract. 2004 Jul 21;5:15
15268764
J Am Geriatr Soc. 2005 Nov;53(11):1912-20
16274372
Am Heart J. 2006 Mar;151(3):713-9
16504638
Europace. 2006 Sep;8(9):651-745
16987906
BMC Public Health. 2007 Aug 10;7:203
17692112
Stroke. 2008 Jan;39(1):7-9
18048849
Chest. 2008 Jun;133(6 Suppl):546S-592S
18574273
Arch Intern Med. 1991 Oct;151(10):1950-3
1929682
Chest. 2010 Feb;137(2):263-72
19762550
Swiss Med Wkly. 2010 Feb 6;140(5-6):73-7
19950036
J Intern Med. 1991 Apr;229(4):351-5
2026988
Chest. 2010 Nov;138(5):1093-100
20299623
Am J Med. 2010 May;123(5):446-53
20399322
BMJ. 2011 Jan 31;342:d124
21282258
Age Ageing. 2011 Nov;40(6):675-83
21821732
Australas J Ageing. 2012 Jun;31(2):102-9
22676169
J Am Coll Cardiol. 2012 Aug 28;60(9):861-7
22858389
Arch Intern Med. 1990 Jan;150(1):83-6
2297300
Hematology Am Soc Hematol Educ Program. 2013;2013:464-70
24319220
Rev Port Cardiol. 2014 Feb;33(2):89-94
24495959
Ther Adv Drug Saf. 2014 Feb;5(1):21-37
25083260
Am J Med. 1989 Aug;87(2):144-52
2787958
Arch Intern Med. 1995 Feb 13;155(3):277-81
7832599
Am Heart J. 1999 Feb;137(2):307-12
9924165